Your search returned 9 results.

Results
	1.	Prevalence in the USA of rilpivirine resistance-associated mutations in clinical samples and effects on phenotypic susceptibility to rilpivirine and etravirine. [electronic resource] by Picchio, Gaston R Rimsky, Laurence T Van Eygen, Veerle Haddad, Mojgan Napolitano, Laura A Vingerhoets, Johan Producer: 20150916 In: Antiviral therapy vol. 19 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors. [electronic resource] by Tambuyzer, Lotke Azijn, Hilde Rimsky, Laurence T Vingerhoets, Johan Lecocq, Pierre Kraus, Guenter Picchio, Gaston de Béthune, Marie-Pierre Producer: 20090414 In: Antiviral therapy vol. 14 Availability: No items available. Save to lists Add to cart (remove)
	3.	Deep sequencing analysis of HIV-1 reverse transcriptase at baseline and time of failure in patients receiving rilpivirine in the phase III studies ECHO and THRIVE. [electronic resource] by Van Eygen, Veerle Thys, Kim Van Hove, Carl Rimsky, Laurence T De Meyer, Sandra Aerssens, Jeroen Picchio, Gaston Vingerhoets, Johan Producer: 20161213 In: Journal of medical virology vol. 88 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. [electronic resource] by Azijn, Hilde Tirry, Ilse Vingerhoets, Johan de Béthune, Marie-Pierre Kraus, Guenter Boven, Katia Jochmans, Dirk Van Craenenbroeck, Elke Picchio, Gaston Rimsky, Laurence T Producer: 20100304 In: Antimicrobial agents and chemotherapy vol. 54 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Long-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naive patients: week 192 results from a phase IIb randomized trial. [electronic resource] by Wilkin, Aimee Pozniak, Anton L Morales-Ramirez, Javier Lupo, Sergio H Santoscoy, Mario Grinsztejn, Beatriz Ruxrungtham, Kiat Rimsky, Laurence T Vanveggel, Simon Boven, Katia Producer: 20120717 In: AIDS research and human retroviruses vol. 28 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial. [electronic resource] by Pozniak, Anton L Morales-Ramirez, Javier Katabira, Elly Steyn, Dewald Lupo, Sergio H Santoscoy, Mario Grinsztejn, Beatriz Ruxrungtham, Kiat Rimsky, Laurence T Vanveggel, Simon Boven, Katia Producer: 20101228 In: AIDS (London, England) vol. 24 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. [electronic resource] by Molina, Jean-Michel Cahn, Pedro Grinsztejn, Beatriz Lazzarin, Adriano Mills, Anthony Saag, Michael Supparatpinyo, Khuanchai Walmsley, Sharon Crauwels, Herta Rimsky, Laurence T Vanveggel, Simon Boven, Katia Producer: 20110729 In: Lancet (London, England) vol. 378 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	8.	Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial. [electronic resource] by Cohen, Calvin J Andrade-Villanueva, Jaime Clotet, Bonaventura Fourie, Jan Johnson, Margaret A Ruxrungtham, Kiat Wu, Hao Zorrilla, Carmen Crauwels, Herta Rimsky, Laurence T Vanveggel, Simon Boven, Katia Producer: 20110729 In: Lancet (London, England) vol. 378 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	9.	Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials. [electronic resource] by Cohen, Calvin J Molina, Jean-Michel Cahn, Pedro Clotet, Bonaventura Fourie, Jan Grinsztejn, Beatriz Wu, Hao Johnson, Margaret A Saag, Michael Supparatpinyo, Khuanchai Crauwels, Herta Lefebvre, Eric Rimsky, Laurence T Vanveggel, Simon Williams, Peter Boven, Katia Producer: 20120612 In: Journal of acquired immune deficiency syndromes (1999) vol. 60 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)